RootPath Genomics

RootPath Genomics develops an immunotherapy platform for cancer treatment, leveraging advanced genomics and cell therapy technologies to create personalized therapeutic approaches. The company's platform focuses on reconstructing T-cell receptor (TCR) repertoires from patient samples, enabling the identification and engineering of T-cells that specifically recognize and target patient-specific tumor neoantigens. This approach allows for the development of precision immunotherapies that are tailored to each patient's unique tumor mutation profile, potentially overcoming the limitations of conventional one-size-fits-all cancer treatments. RootPath's technology combines gene editing, clinical genomics, and cell therapy manufacturing to create a comprehensive platform for precision oncology. The platform addresses key challenges in adoptive T-cell therapy including TCR discovery, TCR engineering, and manufacturing scalability. By leveraging the patient's own immune system through engineered T-cells that target tumor-specific mutations, RootPath aims to develop therapies that are both more effective and less toxic than conventional cancer treatments. The company operates in the intersection of genomics, oncology, immunotherapy, and cell therapy, serving the growing market for precision medicine and personalized cancer treatment. Founded in 2017 and headquartered in Cambridge, United States, RootPath Genomics has raised approximately $68 million at the Series B stage from investors including Sequoia Capital, Baidu Ventures, CDH, Sky9 Capital, Matrix Partners, Hony Capital, Nest Bio Ventures, and Volcanics Venture.

Oncology > In-Vitro Diagnostic Tests > Diversified > Precision Medicine,

Genomics > Enabling Technologies > Technology Platforms > Gene Editing

College Wise > Massachusetts Institute of Technology, University of Toronto